. In the era of routine screening of serum prostate-specific antigen (PSA) levels, the majority of cancers are detected while they are organ confined and hence potentially curable, whereas the incidence of lethal metastatic disease detected at the time of diagnosis has declined 3 . Synthesis of androgens is under the physiological regulation of the hypothalamic-pituitary-testicular axis (FIG. 1a) , with contributions from the adrenal glands resulting from de novo steroidogenesis (FIG. 1b) . Pioneering work by Charles Huggins and colleagues in 1941 demonstrated the remarkable benefit of androgen deprivation therapy (ADT) via surgical castration for men with advanced metastatic prostate cancer 4 , establishing a clinical paradigm that continues to this day. Contemporary first-line ADT for prostate cancer that recurs after prostatectomy or radiotherapy typically involves chemical castration through the chronic use of gonadotropin-releasing hormone (GnRH) agonists or antagonists (TABLE 1) , which lower testosterone levels by stable suppression of androgen secretion from the testes (FIG. 1a) . Combined androgen blockade incorporates the additional use of a competitive androgen receptor (AR) antagonist (an antiandrogen) (TABLE 1) to further impede AR signalling within the prostate cancer cell (FIG. 1c) and to mitigate the effects of acute systemic testosterone surges that result from the initial use of GnRH agonists 5 . Although nearly all patients respond to hormonal therapy, the duration of response varies from months to years, followed by uniform progression to a lethal stage of the disease, termed castration-resistant prostate cancer (CRPC) (FIG. 2a) .
Just over a decade ago, it was generally believed that AR signalling was dispensable to the biology of CRPC. This led to the frequent use of terms such as 'androgen independent' or 'hormone refractory' to describe this stage of the disease. However, an abundance of data acquired since then has made it overwhelmingly clear that residual androgens that remain after castration and AR itself continue to be crucial both for the progression to CRPC and for its continued growth. An early indication of the possible contribution of AR to the progression towards CRPC came from the observation that 30% of patients with CRPC harboured genomic amplification of the AR locus in late-stage tumours but not in patientmatched tumour samples obtained before ADT 6 . In in vitro and in vivo studies using the preclinical prostate cancer models LNCaP and LAPC-4
, our laboratory established that AR overexpression was indeed a sufficient and principal driver of progression to CRPC, as these cells exhibited acquired resistance to both ADT and bicalutamide, the primary anti-androgen in clinical use at that time 7 . These findings provided the rationale for a drug discovery screen of novel anti-androgens that would maintain the ability to inhibit AR signalling Gonadotropin-releasing hormone (GnRH) . Additionally known as luteinizing hormone-releasing hormone (LHRH), GnRH is a small peptide hormone produced in the hypothalamus that stimulates the secretion of luteinizing hormone and folliclestimulating hormone by the pituitary gland.
Luteinizing hormone (LH) . Secreted by the pituitary gland in response to stimulation by gonadotropin-releasing hormone, LH in turn stimulates receptors on Leydig cells of the testes, which leads to synthesis and secretion of testosterone.
CYP17A1
(Cytochrome P450 family 17 subfamily A polypeptide 1). CYP17A1 possesses both 17α-hydroxylase and 17, 20-lyase activities and is a key enzyme in the synthesis of steroid hormones.
in the setting of receptor overexpression, which led to the identification of enzalutamide (formerly known as MDV3100) 8 . In parallel, others developed the CYP17A1 (cytochrome P450 family 17 subfamily A polypeptide 1) inhibitor, abiraterone acetate (hereafter, simply called abiraterone), which targets this central enzyme in de novo steroidogenesis 9 (FIG. 1b) .
Abiraterone and enzalutamide are both approved for the treatment of CRPC in chemotherapy-naive and chemotherapy-refractory patients, based on a series of Phase III trials that showed overall improved survival for either agent used alone versus placebo [10] [11] [12] [13] . Despite the success of these second-generation AR-targeted therapies, inherent or acquired resistance remains a major clinical challenge. In this Review, we examine the current understanding of resistance to contemporary AR inhibition strategies, which we group into the three general categories of restored AR signalling, bypass of AR and complete AR independence (FIG. 2b) . We also discuss implications for the development of the next generation of molecularly targeted therapies for prostate cancer.
Restored androgen receptor signalling
Androgen receptor ligand-binding domain mutations. Early investigations into the mechanisms of resistance to AR-targeted therapies were facilitated by the identification of a point mutation (T878A) within the AR ligand-binding domain (LBD) in the prostate cancer cell line LNCaP 14 , a finding that was soon validated in a patient with CRPC
15
. This discovery spurred investigations by numerous groups to define the frequency of AR mutations in clinical prostate cancer. Collectively, these Figure 1 | AR signalling is regulated by the hypothalamic-pituitary-testicular axis, adrenal gland steroidogenesis and prostate cell intrinsic factors. a | The hormones gonadotropin-releasing hormone (GnRH) and luteinizing hormone (LH) bind to their cognate receptors, resulting in testosterone secretion from Leydig cells of the testes. Chronic use of GnRH agonists leads to downregulation of the GnRH receptor (GnRH-R), whereas antagonists provide immediate GnRH-R blockade. Both agents suppress LH production, which causes a decline in serum testosterone to castrate levels. The adrenal glands secrete the androgens dehydroepiandrosterone sulfate (DHEA-S; predominantly), DHEA and androstenedione (AD) into the circulation. b | Adrenal androgen de novo steroidogenesis (enzymes in ovals). CYP17A1 (cytochrome P450 family 17 subfamily A polypeptide 1 has 17α-hydroxylation (red) and 17, 20-lyase (blue) activities; both are inhibited by abiraterone. The dashed arrow indicates a weak effect. c | Prostate conversion of adrenal androgens to dihydrotestosterone (DHT) is shown in the top right part of the cell. DHT binds to the androgen receptor (AR) in the cytoplasm, triggering a conformational change that leads to nuclear translocation 142, 143 . DHT-bound AR homodimerizes and, with co-activators (CoAs) and RNA polymerase II (RNA Pol II) or co-repressors (not shown), binds to DNA at cis androgen response elements to activate (shown) or repress (not shown) AR target gene expression, respectively [144] [145] [146] [147] . Enzalutamide inhibits AR by competing with DHT for binding, blocking nuclear translocation, and blocking DNA and cofactor binding 8 . AKR1C3, aldo-keto reductase family 1 member C3; 3β-HSD, 3β-hydroxysteroid dehydrogenase/ Δ5-4-isomerase; 17β-HSD, 17β-hydroxysteroid dehydrogenase; SRD5A, steroid 5α-reductase; STS, steryl-sulfatase; SULT2A1, bile salt sulfotransferase.
efforts revealed that AR mutations were detectable in a minority of patients and were exclusively found in men with CRPC but not in those with primary prostate cancer, a finding that was later validated in comprehensive genomic sequencing studies [16] [17] [18] [19] [20] . Of note, these recent investigations, which used next-generation sequencing protocols with deep coverage to discover somatic alterations, found very few mutations within the AR aminoterminal transactivation domain (exon 1). This is in contrast to the plethora of exon 1 mutations reported in the older literature and catalogued in the Androgen Receptor Gene Mutations Database, which were detected using primarily PCR-based protocols 21 . Instead, the LBD has emerged as a mutational hot spot (FIG. 3a) , with four principal point mutations (L702H, W742C, H875Y and T878A) recurring across multiple studies. Collectively, these recurrent AR mutants are present in ~15-20% of CRPC cases, a frequency that grows to >60% when AR gene amplification is included 17, 20 . In vitro characterization of T878A and H875Y revealed that both mutants are paradoxically activated, rather than inhibited, by the anti-androgens nilutamide and flutamide 14, 22 . Hence, an AR antagonist behaves as an agonist in the context of these mutations, which results in the transcriptional induction of AR target genes. In one report, T878A was detected only in those patients who had received combined androgen blockade with flutamide 23 . It has been well documented that discontinuation of flutamide therapy can result in clinical improvement for a subset of patients who had previously responded to the antagonist, the so-called 'anti-androgen withdrawal syndrome' (REF. 24 ). In some patients, this phenomenon is probably caused by the presence of flutamide-activating AR mutations that drive prostate cancer growth during treatment 25 . Curiously, compared with W742C, the flutamide resistance mutations H875Y and T878A occur more frequently (21 of 262 cases) [17] [18] [19] [20] despite the shift to bicalutamide over flutamide as the preferred anti-androgen in clinical practice more than a decade ago. One possible explanation is that these mutations, as well as L702H (which has not been linked to anti-androgen resistance), share the property of promiscuous activation by noncanonical steroid ligands such as adrenal androgens, oestrogen and progesterone 14, 22 or, in the case of L702H, by . Although there is currently no direct evidence that these alternative steroids can promote progression of AR-mutant cancer cells to CRPC, the transcriptional activation data raise the possibility that these alternative steroids could play a substantial part in disease progression. For example, T878A mutations were found in 3 of 18 patients who were progressing on CYP17A1 inhibitors and who had no prior flutamide treatment 33 . The authors proposed increased systemic progesterone levels that resulted from abiraterone treatment as a potential explanation (FIG. 1b) . A second group has also reported H875Y and T878A mutations in circulating cell-free DNA from 11% of patients with CRPC, all of which occurred in the context of progression on, or prior treatment with, abiraterone 30 . In addition, L702H mutations (activated by glucocorticoids) have now been reported in patients receiving abiraterone, which is administered concurrently with the glucocorticoid prednisone to prevent mineralocorticoid excess syndrome caused by inhibition of the 17α-hydroxylase activity of CYP17A1 (REFS 20, 34, 35) . Therefore, the frequent identification of L702H, H875Y and T878A mutations in contemporary patient cohorts may be a consequence of promiscuity towards other steroid ligands rather than anti-androgen resistance.
Androgen receptor splice variants. Alternative splicing of AR mRNA is another mechanism that is implicated in progression to CRPC as well as in resistance to abiraterone and enzalutamide 36, 37 . Although expression of AR splice variants (ARVs) is clearly increased in resistant tumours, the evidence that ARVs play a causal part in resistance remains somewhat controversial, for reasons discussed below. Numerous ARVs have been identified in several prostate cancer cell lines and xenograft tumours at the level of mRNA, and some of them have been confirmed in clinical specimens 20,38-43 . All ARVs share the common structural feature of truncation or exon skipping of the complete carboxy-terminal LBD, typically with a small, variant-specific in-frame sequence added as a consequence of alternative splicing. Importantly, all ARVs retain the amino-terminal transactivation and DNA-binding domains (FIG. 3b) . AR-V7 (also known as AR3) 40 ,41 is the best-characterized ARV, in part owing to the availability of a variant-specific antibody that has enabled analysis of AR-V7 expression in patient samples using immunohistochemistry.
In principle, these structural properties could confer constitutive, androgen-independent activity to all AR isoforms, but in practice only some ARVs display this characteristic in AR transactivation reporter assays. This capability is correlated with constitutive, androgenindependent nuclear localization 39,43 and is explained in part by the presence of a bipartite AR nuclear localization signal located in exons 3 and 4 (REF. AR-V7 is a clear exception, as it does have constitutive nuclear localization and transcriptional activity without a full nuclear localization signal by a mechanism yet to be precisely defined [39] [40] [41] . One point of confusion as to whether ARVs cause resistance is that ARVs are expressed in normal prostate tissue 40, 45 , and ARV levels in prostate cancer are physiologically increased in response to ADT. It has long been known that ADT leads to a rapid increase in AR mRNA levels in prostate tissue that is reversed by androgen replacement 46, 47 . Similar results, including proportional increases in ARV expression, are seen in human The majority of patients relapse with typical AR-positive adenocarcinoma with rising PSA levels. Although the incidence is not precisely defined, a subset of relapsing patients present with AR-low or AR-negative tumours and low levels of PSA. The histological classification of these cancers is an area of active investigation, but they include classic small-cell carcinoma (SCC), neuroendocrine prostate cancer (NEPC) in the absence of SCC histological features, and potentially emerging, novel subtypes. Known or suspected molecular drivers of resistance are shown. Note that these molecular alterations are not mutually exclusive to each class, and some degree of overlap occurs in model systems and is likely to occur in patients. AURKA, Aurora kinase A; DHT, dihydrotestosterone; GR, glucocorticoid receptor. prostate cancer xenograft tumours. Protein levels of both AR-FL (the canonical full-length AR) and AR-V7 were increased in a reversible manner 2 days after castration of mice bearing VCaP tumours, reaching a peak at 2 weeks. Importantly, at all time points analysed, AR-V7 mRNA levels constituted only a small fraction of AR-FL levels 39 . Conversely, AR-FL and AR-V7 mRNA levels in castration-resistant and abiraterone-resistant VCaP tumours were decreased 24 hours after androgen treatment 48 . One mechanism of AR autoregulation involves the binding of AR to a classic androgen response element in an AR intron in conjunction with lysine-specific histone demethylase 1A (KDM1A), resulting in the repression of AR transcription 49 . In VCaP and a derivative line of LNCaP, ADT can also promote the redistribution of splicing factors, which enables synthesis of AR-V7 (REF. 50 ). Therefore, physiological feedback mechanisms triggered by ADT could be responsible for the increased levels of ARVs and AR-FL observed in patients with prostate cancer.
In contrast to these physiological explanations for ARV expression (which are unlikely to explain resistance because they would occur from months to years before progression to CRPC), there are other contexts in which ARV expression does confer resistance to antiandrogen therapy. The best evidence comes from the 22Rv1 cell line derived from the CWR22 xenograft, which expresses high levels of AR-V7 and is resistant to enzalutamide. Importantly, short interfering RNA (siRNA)-mediated knockdown of AR-V7 restored sensitivity to enzalutamide 51 . In this model, it seems that AR-V7 can completely replace the function of AR-FL. However, this is not the case in VCaP cells, which also express AR-V7 but remain sensitive to androgen depletion or enzalutamide 8, 39, 48 . One important difference is that AR-V7 levels are substantially higher in 22Rv1 cells, particularly when considered relative to AR-FL levels. These high levels in 22Rv1 cells may be explained by intragenic duplications and rearrangements within the AR locus, which have also been reported in some patients 52, 53 . Confusingly, forced expression of AR-V7 at high levels in various ADT-sensitive models is not sufficient to confer resistance to castration or to enzalutamide. Overexpression of AR-V7 in ARV-negative LNCaP cells did not confer resistance to enzalutamide in vitro or in vivo, even though AR-V7 promoted tumour growth in mice that were treated with castration alone Given the limitations of preclinical models, the confusion about the role of AR-V7 (and other ARVs) in resistance will only be resolved through carefully executed studies in patients. Two recent reports in small cohorts of men with heavily pretreated CRPC (with multiple lines of hormonal therapies post-docetaxel) showed that AR-V7 expression correlated with primary resistance to abiraterone or enzalutamide 56, 57 . It will be important to see whether these results are confirmed in larger
Box 1 | Human prostate cancer model systems
Research in the prostate cancer field has historically been hampered by a limited number of human cell lines and xenograft models. Cell lines derived from non-metastatic, primary prostate cancer are particularly poorly represented. Consequently, discoveries in the field generally result from the study of only a few major cell lines (detailed below). Nevertheless, clinically relevant resistance mechanisms have been identified through the use of these models. Finally, recent refinements in tissue culture methodologies, particularly serum-free conditions for the growth of tumour organoids, have enabled the development of several additional prostate cancer lines that recapitulate common genomic alterations seen in patients with prostate cancer 127 . 
Cell

Cistrome
The collection of DNA elements within a genome that are bound by a transcription factor.
cohorts of men with less advanced disease, for which the ratio of ARV expression relative to AR-FL expression is expected to be substantially lower 20, 39, 41, 45 .
Adrenal androgens and intraprostatic testosterone and DHT synthesis. Testosterone is produced by the testes and is the principal circulating androgen. Within tissues, testosterone is converted into the more potent androgen, dihydrotestosterone (DHT), through one of two iso enzymes, steroid 5α-reductase 1 (SRD5A1; also known as 3-oxo-5α steroid 4-dehydrogenase 1) or SRD5A2, both of which are targets of the drug dutasteride 58 . SRD5A2 predominates within the normal prostate, whereas the liver and skin express primarily SRD5A1 (REF. 59 ). Medical or surgical castration reduces circulating levels of serum testosterone by >90% 60 ; however, physiologically significant amounts of intraprostatic androgens remain after ADT in localized prostate cancer 60,61 , metastatic CRPC 62 and even in benign prostates from healthy men 63 . A primary source of these residual prostatic androgens are the adrenal androgens dehydro epiandrosterone (DHEA) and androstenedione (AD), which are converted into testosterone and DHT in the prostate (FIG. 1c) . DHEA and AD are products of de novo steroidogenesis in the adrenal gland (as well as in the testis), which begins with cholesterol. CYP17A1, the target of abiraterone, regulates two successive reactions to convert pregnenolone into DHEA, whereas AD arises predominantly from DHEA (FIG. 1b) . DHEA also exists in a sulfated form (DHEA-S), which is the predominant adrenal androgen in circulation. Levels of both DHEA and AD are significantly reduced in patients with CRPC who are treated with abiraterone, but a persistent pool of DHEA-S could serve as a precursor for conversion into testosterone and DHT in prostate tissue 64 .
In prostate cells, AD is ultimately converted into DHT through the classic route by aldo-keto reductase family 1 member C3 (AKR1C3) 65, 66 , or by a testosteroneindependent pathway 67 (FIG. 1c) . There is growing evidence that AKR1C3 could be a relevant drug target for CRPC, particularly in the context of enzalutamide-resistant cell lines 68, 69 , and several potential inhibitors have been reported 70 . Another enzyme in androgen biosynthesis that has gained recent attention is 3β-hydroxysteroid dehydrogenase/Δ5-4-isomerase type 1 (3β-HSD1; encoded by HSD3B1), which converts DHEA into AD in prostate tissue as well as in the adrenal gland. A gain-of-function allele of HSD3B1 is found in some samples from patients with CRPC and some cell lines (for example, LNCaP and VCaP); the resulting 3β-HSD1 protein has enhanced stability and therefore increases the metabolic conversion of DHEA into intraprostatic DHT 71 . This allele can exist as a heterozygous germline polymorphism, but there is strong evidence for somatic mutation based on the frequency of homozygous alleles in CRPC samples. Collectively, these examples underscore the potential value of further blockade of androgen biosynthesis downstream of CYP17A1.
Androgen receptor bypass signalling Recent work reveals a novel AR pathway resistance mechanism analogous to one originally described for kinase inhibitors, in which signalling downstream of the targeted kinase is restored by the activation of a related kinase not targeted by the inhibitor 72 . In the context of kinase inhibitors, the clinical impact of this escape mechanism is well established in epidermal growth factor receptor (EGFR)-mutant lung cancer and BRAF-mutant melanoma, and is widely referred to as 'bypass' signalling to emphasize the sustained importance of the initial oncogenic pathway that is alternatively activated by a different driver. Two groups have now documented an analogous mechanism for hormone receptors 73, 74 . (To avoid confusion, we note that the term 'bypass' was used in earlier reviews of castration resistance to describe mechanisms that are completely independent of AR 75, 76 . In light of the contemporary analogy with kinase inhibitors, we suggest that 'bypass' in this context is better suited to refer to mechanisms in which downstream hormone receptor pathway signalling remains relevant but through activation by a different hormone receptor, as described below.) In the LNCaP xenograft model with exogenous AR overexpression (LNCaP-AR) 7 , acquired resistance to enzalutamide or ARN-509 correlated with the upregulation of the glucocorticoid receptor (GR), as revealed by transcriptome analysis 74 . An LNCaP-AR subline termed LREXʹ, with acquired resistance to enzalutamide, was shown to be dependent on GR expression for enzalutamide-resistant growth. In VCaP cells, glucocorticoidmediated activation of the comparatively lower level of endogenous GR was sufficient to confer enzalutamide resistance. ChIP-seq (chromatin immunoprecipitation followed by sequencing) and mRNA expression analysis of AR and GR revealed highly overlapping cistrome and transcriptome profiles for the two receptors 74, 77 . In the resistant LREXʹ tumours, GR induction was associated with restored expression of a restricted subset of AR target genes that are presumed to mediate resistance. Analysis of bone marrow biopsies from patients treated with enzalutamide supported a role for GR induction in clinical resistance to enzalutamide 74 . Recent data presented at the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting suggested that GR bypass may occur in earlier stages of disease. Tumour cells in men with high-risk localized prostate cancer with early resistance to neoadjuvant chemical castration plus abiraterone also expressed significant levels of GR 78 . It is worth highlighting that active AR inhibition is necessary to maintain high levels of GR expression in preclinical models, owing to the active repression of GR expression by AR binding to the GR (also known as NR3C1) locus. For this reason, it may be important to obtain clinical specimens from patients who are undergoing active anti-androgen treatment to fully evaluate the importance of GR as a resistance mechanism 74 . At first glance, the hypothesis that GR can confer resistance may seem inconsistent with clinical evidence that glucocorticoid administration can be beneficial to some patients with CRPC. This apparent paradox is explained by the fact that glucocorticoids inhibit adrenocorticotropic hormone (ACTH) production by the pituitary gland, which results in reduced androgen levels 79 (FIG. 4a) . This androgen-lowering activity explains the decline in serum PSA levels that is observed in men taking prednisone alone, which was documented in the comparator arm of the Phase III clinical trial that led to approval of abiraterone for chemotherapy-naive CRPC 80 . However, in men with prostate cancers that express high levels of GR, this androgen-lowering benefit would be counteracted by GR activation in tumour cells (FIG. 4b) .
In this setting, a more effective treatment strategy could be combined inhibition of AR and GR, as is currently being explored in an early-phase clinical trial of enzalutamide in combination with the GR antagonist mifepristone (ClinicalTrials.gov identifier: NCT02012296). One potential confounder of this study is the fact that mifepristone also has a high binding affinity for AR and can function as an AR agonist 81 . Therefore, mifepristone treatment could unintentionally result in AR activation through agonism by displacing the potent antagonism of enzalutamide. Also of concern is that, in an earlier singleagent Phase II study 82 , mifepristone treatment resulted in higher androgen levels, probably owing to GR inhibition in the pituitary gland, with a subsequent increase in the levels of ACTH and adrenal androgens (the opposite effect of glucocorticoid administration). It will be important to document combined AR and GR inhibition in tumour cells from patients treated in the ongoing combination therapy trial; otherwise, a lack of clinical benefit could be a result of AR reactivation by mifepristone.
In addition to GR, the progesterone receptor (PGR) and the mineralocorticoid receptor (MR) are also steroid hormone nuclear receptor family members that are structurally related to AR, and that share substantial homology within the DNA-binding domain 83 . As with GR, it is possible that PGR or MR could transcriptionally regulate a subset of AR target genes in prostate cancer, and thereby bypass AR. PGR expression has been demonstrated in prostate tumour cells in some 84, 85 although not all 86, 87 studies. Interestingly, in a recent, large retrospective analysis, high PGR staining in primary prostate cancer was associated with clinical recurrence 84 . There is less evidence implicating MR, but it is worth noting that the gene encoding MR, NR3C2, was among the top upregulated genes in VCaP xenograft tumours with acquired resistance to abiraterone 48 .
Complete androgen receptor independence
It has long been known that metastatic CRPC displays a remarkable degree of inter-and intra-patient molecular heterogeneity 20, [88] [89] [90] . Heterogeneity also extends to the distribution and intensity of AR expression, as revealed by immunohistochemical studies of CRPC bone metastases 89, [91] [92] [93] . For example, in a study of bone metastases from 44 patients with CRPC, 58.1% of those cases had moderate (30.4% of cases) to intense (69.6% of cases) AR staining in 76-100% of the tumour cells, whereas 8.8% of the patients in the study had AR staining in just 1-25% of tumour cells 93 . Thus, metastatic CRPC can exist as a mixture of cells that display a range of AR expression levels.
With the growing clinical use of abiraterone and enzalutamide, it is increasingly appreciated that some men can relapse with clinically aggressive variants of prostate cancer with reduced or absent AR expression. Although the precise histological classification of these subtypes continues to be refined, they are often found to express markers of neuroendocrine differentiation (NED) (chromogranin A, synaptophysin and neural cell adhesion molecule) and may also show histological features of small-cell carcinoma (SCC), a rare variant of AR-negative primary prostate cancer also displaying NED [94] [95] [96] . To add Figure 4 | Opposing roles of glucocorticoids in prostate cancer. a | Glucocorticoids (GCs) negatively regulate adrenocorticotropic hormone (ACTH) production from the pituitary gland, which in turn diminishes adrenal androgen production. As a consequence, there is less conversion of adrenal androgens to dihydrotestosterone (DHT). This effect is observed clinically in some patients who receive an exogenous GC (such as prednisone or dexamethasone) by a decline in androgen receptor (AR) activity as measured by prostate-specific antigen levels 79, 148 . b | In other situations, GCs can directly stimulate tumour proliferation by activating AR target gene expression. One mechanism is by GCs out-competing enzalutamide for binding to AR target genes in tumour clones carrying the AR L702H mutation, which is stimulated by GCs. Another route is GC activation of tumours by direct activation of glucocorticoid receptor (GR) in tumours, which thus acquire GR expression, thereby bypassing the blockade of AR target gene expression by enzalutamide. WT, wild type.
further complexity, tumour cells with NED can often be found mixed with usual adenocarcinoma cells 96 , but the relevance of these subpopulations to the disease course is unclear. Molecular profiling of prostate cancer with NED has revealed loss of RB1, PTEN and TP53 mutations as well as amplification of MYCN and Aurora kinase A (AURKA) 97, 98 . MYCN overexpression in LNCaP resulted in the induction of NED features concurrent with downregulation of AR and AR target genes 98 . Conditional deletion studies in mice provide strong evidence of a causal role for loss of both RB1 and TP53 in the genesis of metastatic CRPC with NED, although tumours in these mice retained heterogeneous expression of AR and luminal epithelial cytokeratins 99 . Conversely, RB1, PTEN and TP53 deletions and mutations are observed in CRPC with usual adenocarcinoma histology, so the association with NED is not absolute 20 . It is unclear whether AR-negative prostate cancers arise directly from typical AR-positive adenocarcinomas by a process of transdifferentiation or instead from a population of AR-negative neuroendocrine cells present in the normal prostate. Evidence supporting transdifferentiation comes from multiple studies showing the presence of the AR-regulated TMPRSS2-ERG genomic translocation by fluorescence in situ hybridization in AR-negative SCC 100-102 at a frequency akin to that seen in AR-positive adenocarcinoma 103 . These findings are consistent with earlier observations that LNCaP cells can acquire expression of some neuroendocrine markers upon prolonged ADT 104 . As CRPC undergoes temporal clonal selection in response to treatment 34 , there is concern that the widespread and long-term use of next-generation AR inhibitors could increase the prevalence of prostate cancer with loss of AR and NED. At present, it is still too early to know whether this concern is justified. One recent genomic landscape study of 150 patients with CRPC, which included many with prior exposure to abiraterone or enzalutamide, suggests that this may not be the case, as more than 96% of cases had usual adenocarcinoma histology. Subtypes of adenocarcinoma with NED comprised just 2.9% of cases, whereas SCC comprised only 0.7% 20 . However, another study presented at the 2015 ASCO Annual Meeting reported that of 101 cases of CRPC resistant to abiraterone or enzalutamide only 33% displayed typical adenocarcinoma histology, and 12% displayed SCC histology; 27% of cases showed an intermediate histology that was distinct from SCC or typical adenocarcinoma 105 . Further analyses of contemporary CRPC cohorts, with careful attention to potentially new emerging histological subtypes, will be crucial in resolving this issue.
Future therapeutic options for CRPC
Despite the clinical successes of abiraterone and enzalutamide as single-agent therapies for metastatic CRPC, it is clear that additional therapeutic advances are needed. One possibility is that the efficacy of both drugs may increase substantially when they are used much earlier in the disease course, as has been seen routinely with kinase inhibitors for various cancers. Clinical trials addressing this question are under way in men with pre-metastatic CRPC (also called M0 disease) and as front-line therapy in men with hormone-sensitive disease (ClinicalTrials.  gov identifiers: NCT02058706, NCT01664923,  NCT02003924, NCT01927627, NCT01715285,  NCT01957436, NCT02064582, NCT02023463,  NCT02028988, NCT01751451, NCT01023061 and  NCT02203695 ). In addition, it is possible that combination therapy with abiraterone and enzalutamide may be more effective than either drug used alone, as they attack AR signalling by distinct mechanisms. This hypothesis is also being tested in several clinical trials (ClinicalTrials.gov identifiers: NCT01949337, NCT01650194, NCT02268175 and NCT02125357). Sequential studies using one of these agents, followed by second-line treatment with the other, have shown responses in some patients, but the overall impact has been modest [106] [107] [108] [109] [110] [111] . Recent findings that a metabolite of abiraterone, Δ 4 -abiraterone, is also a potent AR antagonist on par with enzalutamide may provide an explanation for cross-resistance between enzalutamide and abiraterone 112 . Although sequential or combined abiraterone and enzalutamide therapy may be insufficient to control CRPC, recent genomic landscape studies that use either tumour biopsies or circulating cell-free DNA sampling show that AR amplification is present in 45-52% of the cancers, which underscores the sustained importance of AR in late-stage disease 20, 30 . These results justify continued endeavours to discover novel AR-focused treatment strategies. The most advanced efforts involve compounds that continue to be directed against the LBD of AR and CYP17A1, but it remains to be seen whether these agents can overcome the cross-resistance that is seen after prior treatment with abiraterone or enzalutamide. Several novel AR-targeting methods that bypass the conventional approach of interfering with ligandmediated AR activation are under investigation. These include small-molecule inhibitors directed against the N-terminal transactivation domain 113 or the DNAbinding domain 114 . These molecules offer the additional advantage of efficacy against all isoforms of AR, including ARVs. Another strategy is to pharmacologically trigger AR degradation, given the analogous success with the oestrogen receptor degrader fulvestrant, which has been used for the treatment of metastatic breast cancer that progressed after failure of first-line anti-oestrogen therapy 115 . Trials of AZD3514, a purported AR degrader, showed that PSA levels declined in 13% of patients with CRPC, but clinical development was halted because of gastrointestinal toxicity 116 . In addition to the sustained role of AR, another important insight from CRPC genomic landscape studies is the number of molecular alterations in other actionable pathways, including PI3K-AKT-PTEN, RAF, WNT, DNA repair and the cell cycle 20 (cBioPortal). Numerous inhibitors of the PI3K-AKT-mTOR pathway have shown activity in preclinical models, often in combination with next-generation AR therapy, and are under study in clinical trials in CRPC [117] [118] [119] . Perhaps the most unexpected finding is the high frequency of germline and somatic mutations in genes that encode proteins in DNA repair pathways, such as BRCA1, BRCA2 and ataxiatelangiectasia mutated (ATM). BRCA1-and BRCA2-deficient tumour cells are deprived of normal repair of DNA breaks through homologous recombination, and thus become highly sensitized to inhibitors of the DNA repair enzyme, poly(ADP-ribose) polymerase 1 (PARP1) 120, 121 . One such inhibitor, olaparib, is now approved for the treatment of advanced ovarian cancer in women with germline mutations in BRCA1 or BRCA2, and others are in late-stage clinical development. The ovarian cancer experience has sparked analogous PARP inhibitor trials in CRPC [122] [123] [124] [125] . Although still early, overall response rates have been encouraging and include several exceptional responses in men with BRCA mutations.
Looking forward, it seems likely that the standard of care for CRPC will evolve towards distinct molecular subclasses with individualized therapies, as has already occurred in other tumour types such as lung adenocarcinoma. We base this prediction on the unexpectedly high percentage of patients with potentially actionable mutations 20 , together with the now demonstrable feasibility of testing for these mutations in biopsies of metastatic lesions as well as in circulating tumour cells and circulating cell-free DNA 30, 126 . This shift in clinical practice will be driven by a compelling new treatment option, analogous to lung cancer and EGFR inhibitors. Assuming the early clinical data are confirmed, this will probably be treatment with PARP inhibitors, and perhaps cisplatin chemotherapy, in patients with BRCA1 or BRCA2 mutations. We anticipate that this approach will rapidly expand beyond traditional singlegene tests (companion diagnostics) to multi-gene sequencing platforms that are capable of identifying an array of mutations that will steer patients to appropriate clinical trials. Based on the high frequency of mutations observed in PI3K pathway genes (PTEN, PIK3CA and PIK3CB) in CRPC, we predict that there will be increased focus on clinical trials of PI3K inhibitors, particularly those selective for the p110α and p110β isoforms, in this subset of patients. Patients with complete AR independence are more challenging, as there is currently little insight into actionable mutations for this subset. With growing evidence that lineage plasticity or transdifferentiation (and associated changes in chromatin landscape) may precipitate the transition to complete AR independence, the focus may shift to prevention of this transition using drugs that target chromatin-modifying enzymes. Whether AR-focused treatment will remain the backbone of treatment for all men with metastatic prostate cancer remains to be determined.
Summary
The survival advantage seen as a result of treatment with either enzalutamide or abiraterone in patients with metastatic CRPC has further solidified the importance of AR even in late-stage disease. However, inherent or acquired resistance to these agents remains a major clinical obstacle, and a greater understanding of biomarkers of response as well as mechanisms of resistance is urgently needed. Multiple mechanisms of resistance to AR-targeted therapies have been identified -AR overexpression with or without amplification, AR mutations, ARVs, intratumoural DHT synthesis, GR overexpression and loss of AR -and others undoubtedly remain to be discovered. Because of the multiclonal and heterogeneous nature of prostate cancer, it is probable that multiple mechanisms of resistance may be operating concurrently in any given patient, and these may also change temporally in response to sequential treatments. Clinical trials that collect biopsies of metastases before the onset of a new treatment and again at the emergence of resistance, coupled with integrative genomic analysis, should help to identify these evolving resistance mechanisms, which could then ideally be acted upon to improve patient outcomes. In addition, insights gained through the ongoing efforts to classify molecular subtypes of prostate cancer according to their genomic profiles should continue to identify candidate driver mutations that will better inform clinical trial design. In the long term, success will most probably come from early and aggressive treatment of high-risk patients with combinations that are tailored to prevent resistance before tumours evolve to genomically complex stages. 
